-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Cellebrite DI, Lowers Price Target to $16

Benzinga·08/14/2026 16:19:08
Listen to the news
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.